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ABSTRACT
Melanoma ranks among the most aggressive and deadly human cancers. Although 
a number of targeted therapies are available, they are effective only in a subset of 
patients and the emergence of drug resistance often reduces durable responses. 
Thus there is an urgent need to identify new therapeutic targets and develop more 
potent pharmacological agents for melanoma treatment. Herein we report that SHP2 
levels are frequently elevated in melanoma, and high SHP2 expression is significantly 
associated with more metastatic phenotype and poorer prognosis. We show that 
SHP2 promotes melanoma cell viability, motility, and anchorage-independent growth, 
through activation of both ERK1/2 and AKT signaling pathways. We demonstrate that 
SHP2 inhibitor 11a-1 effectively blocks SHP2-mediated ERK1/2 and AKT activation and 
attenuates melanoma cell viability, migration and colony formation. Most importantly, 
SHP2 inhibitor 11a-1 suppresses xenografted melanoma tumor growth, as a result of 
reduced tumor cell proliferation and enhanced tumor cell apoptosis. Taken together, 
our data reveal SHP2 as a novel target for melanoma and suggest SHP2 inhibitors as 
potential novel therapeutic agents for melanoma treatment.
INTRODUCTION
Melanoma is a malignant tumor of melanocytes and 
ranks among the most common cancers in the United States. 
Melanoma is also among the most aggressive human cancers, 
with 1- and 2-year survival rates in patients with metastatic 
melanoma of ~25% and 10%, respectively, and a median 
overall survival of 6 months. New treatments for melanoma 
have been developed over the past few years, including a 
number of molecular targeted and immunotherapeutic 
approaches. However, these targeted approaches are usually 
effective only in a subset of patients and the emergence of 
drug resistance further reduces durable responses [1]. These 
limitations highlight the need for better understanding of the 
mechanisms of pathogenesis and acquired drug resistance 
in melanoma, identification of new therapeutic target, and 
discovery of more potent pharmacological agents.
Several key signaling pathways and molecules 
have been implicated in the onset and progression of 
melanoma [1–3]. The extracellular signal-regulated kinase 
(ERK1/2) pathway, which controls key cellular processes 
such as proliferation, invasion, and survival, is frequently 
activated in human cancers including melanoma. Mutations 
of components in this pathway leading to constitutive 
activation of ERK1/2 are often associated with melanoma 
development [4]. The PI3K-AKT pathway is also 
implicated in melanoma. Constitutive activation of PI3K-
AKT pathway facilitates melanoma progression, possibly 
by enhanced cell survival [5]. Phospho-AKT level increases 
dramatically during melanoma progression and invasion 
and is inversely correlated with patient survival [6]. Several 
growth factor receptors acting upstream of ERK1/2 and 
PI3K-AKT cascades are also implicated in melanoma. 
For example, hepatocyte growth factor receptor, c-Met, is 
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expressed and activated in melanoma tissues and cell lines 
[7]. Overexpression of c-Met is associated with melanoma 
progression and metastasis [8, 9], and constitutive activation 
of c-Met signaling promotes melanoma metastasis 
in mice [10]. Stem cell factor receptor, c-KIT, is an 
important receptor tyrosine kinase involved in melanocyte 
development, migration, and survival. Melanoma arising 
from mucosal, acral, and chronically sun-damaged sites 
commonly has amplifications or activating mutations in 
KIT [11].
SHP2, encoded by PTPN11, is a protein tyrosine 
phosphatase that promotes both ERK1/2 and PI3K-
AKT signaling [12–15]. Germline mutations in 
PTPN11 cause Noonan and LEOPARD syndromes 
[16, 17], while somatic mutations in PTPN11 have 
been linked to childhood and adult malignancies [18, 
19]. Increased SHP2 expression has been recognized 
as a prognostic and predictive marker in gastric, 
breast, oral, prostate, lung, head and neck, thyroid, 
liver and pancreatic cancers [20–28]. Most recently, 
SHP2 overexpression and mutations were also found 
in melanoma patient samples [29–31]. In addition, 
given the obligatory requirement of SHP2 in signaling 
pathways mediated by receptor tyrosine kinases, 
many of which are up-regulated in melanoma, SHP2 
may also be required for melanoma pathogenesis and 
progression. In the current study, we provide evidence 
that SHP2 promotes melanoma cell viability, motility, 
migration and anchorage-independent growth, likely 
due to the observed positive regulation of ERK1/2 and 
AKT pathways. We demonstrate that a specific SHP2 
inhibitor 11a-1 [32] effectively suppresses SHP2’s 
positive effects on multiple cellular processes as well 
as ERK1/2 and AKT signaling pathways in melanoma 
cell. Most importantly, 11a-1 significantly suppresses 
xenografted melanoma tumor growth, validating SHP2 
as a novel target for melanoma and SHP2 inhibitors as 
potential therapeutic avenue for melanoma treatment.
RESULTS
The clinical relevance of SHP2 in melanoma
To explore the clinical significance of SHP2 in 
melanoma, we analyzed PTPN11 mRNA level in the 
Oncomine database [33, 34]. PTPN11 mRNA level in 
cutaneous melanoma appeared higher than that in normal 
skin although without statistical significance (p = 0.0558), 
probably due to the small sample size for normal skin 
tissue (Figure 1A). Notably, when compared to the benign 
melanocytic skin nevus, which is commonly viewed as the 
precursor of melanoma, PTPN11 mRNA was significantly 
up-regulated in melanoma (Figure 1A). We also compared 
PTPN11 mRNA level between primary and metastatic 
melanoma samples in the skin cutaneous melanoma dataset 
in the TCGA database [35, 36]. As shown in Figure 1B, 
PTPN11 mRNA is significantly elevated in metastatic 
melanoma versus primary melanoma. Most importantly, 
the Kaplan-Meier survival analysis for patients in this 
dataset revealed that the high PTPN11 mRNA expression 
group showed significantly shorter overall survival time 
compared to the low PTPN11 mRNA group, with a median 
survival of 24.03 months versus 35.67 months (Figure 1C). 
Collectively, these clinical data suggest that SHP2 may 
play a role in melanoma onset and progression, and thus 
targeting SHP2 may be beneficial for melanoma treatment.
SHP2 promotes melanoma cell viability, motility 
and anchorage-independent growth
Although SHP2 expression is elevated in melanoma, 
the role of SHP2 in melanoma is unknown. To investigate 
the biological function of SHP2 in melanoma, we firstly 
examined the effect of SHP2 modulation on melanoma 
cell viability. To this end, we either overexpressed or 
knocked down SHP2 in MeWo melanoma cells and 
measured the cell viability by the MTT assay. As shown 
Figure 1: SHP2 shows clinical significance in melanoma. A. PTPN11 mRNA is up-regulated in melanoma tissues. Data are shown 
as mean±SD. B. PTPN11 mRNA is further elevated in metastatic melanoma versus primary melanoma. Data are shown as mean±SD. 
C. Higher PTPN11 mRNA shortens melanoma patient survival. PTPN11 mRNA and survival time were extracted respectively from RSEM 
normalized mRNAseq and merged clinical data for patients in TCGA skin cutaneous melanoma study.
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in Figure 2A, SHP2 overexpression increased cell 
viability by ~30% and SHP2 knockdown decreased that 
by ~20%. To gain insights into the positive role of SHP2 
in melanoma cell viability, we examined the proliferation 
marker PCNA and apoptosis marker cleaved PARP after 
SHP2 overexpression or knockdown in MeWo cells 
(Figure 2B). PCNA was increased and cleaved PARP was 
reduced in SHP2 overexpressed cells. Conversely, PCNA 
was decreased and cleaved PARP was increased in SHP2 
knockdown cells. Together, the data indicates that SHP2 
promotes melanoma cell viability through enhancing cell 
proliferation and suppressing apoptosis. To strengthen 
this conclusion, SHP2 overexpression or knockdown 
MeWo cells were stained with Hoechst and anti-Ki67 
antibody, and the Ki67-positive cells were visualized and 
analyzed by an ArrayScan high-content screening system. 
Consistently, the number of Ki67-positive cells increased 
following SHP2 overexpression and decreased after SHP2 
knockdown (Figure 2C).
Increased cell motility is one of the defining 
characteristics of invasive tumors and is crucial to 
tumor invasion and metastasis [37]. To assess the 
effect of SHP2 on melanoma cell motility, MeWo cells 
overexpressing SHP2 or vector control were stained 
with Hoechst and monitored by an ArrayScan high-
content screening system. Compared to vector control, 
SHP2 overexpression clearly increased the mean 
moving distance of melanoma cells at the same time 
point (Figure 2D) and led to ~1.4-fold increase in the 
mean speed of cell movement by the end of 4 hours 
observation window (Figure 2E). We also carried out 
wound healing experiment to further evaluate the effect 
Figure 2: SHP2 promotes melanoma cell viability, motility, and anchorage-independent growth. A. SHP2 overexpression 
enhances MeWo cell viability, and SHP2 knockdown reduces MeWo cell viability. B. SHP2 overexpression in MeWo cell enhances 
proliferation and supresses apoptosis, and SHP2 knockdown supresses proliferation and enhance apoptosis. C. SHP2 overexpression in 
MeWo cell increases Ki67-positive (i.e. proliferative) cells, and SHP2 knockdown decreases Ki67-positive cells. SHP2 overexpression 
promotes MeWo cell D. movement E. moving speed F. migration and H. anchorage-independent growth. G. SHP2 knockdown slows down 
the MeWo cell migration.
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of SHP2 on cell motility. As shown in Figure 2F and 
2G, SHP2 overexpression sped up MeWo cell migration 
by 1.6 folds, whereas SHP2 knockdown slowed down 
MeWo cell migration by 30%.
Anchorage-independent growth is a hallmark of 
oncogenic transformation and a key characteristic of 
cancer cells [38], and the in vitro anchorage-independent 
growth of cancer cells has been connected with tumor 
cell aggressiveness in vivo such as tumorigenic and 
metastatic potentials [39]. Thus we also investigated 
the effect of SHP2 on anchorage-independent growth 
of MeWo cell using colony formation assay. Compared 
to vector control, larger and 45% more colonies were 
observed in SHP2 overexpressing melanoma cells 
(Figure 2H). Collectively, the above results indicate that 
SHP2 promotes melanoma cell viability, motility, and 
anchorage-independent growth.
SHP2 positively regulates ERK1/2 and PI3K/
AKT pathway in melanoma cells
ERK1/2 and PI3K/AKT are the two major signal 
pathways implicated in melanoma pathogenesis and 
progression [2], and SHP2 is a recognized positive 
regulator of Ras, which activates both pathways [12–15]. 
Thus, we examined the effect of SHP2 on both ERK1/2 and 
PI3K-AKT pathways in MeWo cells. As shown in Figure 
3A, compared to the vector control, ERK1/2 activation is 
significantly enhanced in SHP2 overexpression cells. We 
then assessed the phosphorylation of Paxllin (Y118), a 
physiological substrate of SHP2 required for Src activation 
[40]. SHP2 promotes the activation of Src family kinases 
through dephosphorylation of Paxillin (Y118), thereby 
preventing Csk from phosphorylating the C-terminal 
inhibitory Tyr527 in Src kinase [40, 41]. As expected, the 
pPaxillin (Y118) and pSrc (Y527) levels are decreased 
in SHP2 overexpressed cells, thereby contributing to 
ERK1/2 activation. SHP2 overexpression also promotes 
AKT activation, leading to enhanced phosphorylation 
of the downstream S6K which might contribute to the 
positive role of SHP2 on cell proliferation. To consolidate 
the above effects of SHP2 on both ERK1/2 and AKT 
signal pathways, we also determined the effects of SHP2 
knockdown in MeWo cells. As expected, both pPaxillin 
(Y118) and pSrc (Y527) are elevated, and ERK1/2, AKT 
and S6K activation are diminished when SHP2 level is 
reduced (Figure 3B). Since c-Met is a receptor tyrosine 
kinase involved in melanoma [7, 8, 10], we further 
evaluated whether SHP2 could affect aforementioned 
signals upon HGF stimulation (Figure 3C). As expected, 
SHP2 knockdown diminishes the dephosphorylation of 
Paxillin pY118 and Src pY527, and attenuates ERK1/2, 
AKT and S6K activation after HGF stimulation, and the 
alterations on these signaling molecules are more obvious 
compared to those without HGF stimulation in Figure 
3B. Collectively, these results reveal that SHP2 plays a 
positive role in promoting ERK1/2 and AKT pathways in 
MeWo melanoma cells.
SHP2 inhibitor 11a-1 reduces melanoma cell 
viability, motility, and anchorage-independent 
growth
Given the observed positive role of SHP2 in 
promoting melanoma cell viability, motility, anchorage-
independent growth, as well as ERK1/2 and PI3K/AKT 
pathway activation, we speculated that pharmacological 
inhibition of SHP2 could counteract these positive effects 
thereby benefit melanoma treatment. Thus we used a 
potent and specific SHP2 inhibitor 11a-1 [32] to validate 
the potential of targeting SHP2 for melanoma treatment. 
We first evaluated 11a-1’s cellular effect on melanoma cell 
viability by the MTT assay. As shown in Figure 4A, 11a-
1 dose-dependently inhibits MeWo cell viability with an 
EC50 of 4.2 μM and a maximum inhibition of ~70%, but a 
structurally-related, inactive analog 10c [32] did not show 
any inhibition up to 20 μM, indicating that 11a-1 suppress 
melanoma cell viability through inhibiting SHP2. Similar 
inhibitory effect for 11a-1 on cell viability was also 
observed in a mouse melanoma cell line B16F10, with 
an EC50 of 5.1 μM and a maximum inhibition of ~95% 
(Supplementary Figure S1A). To further ascertain target 
engagement by 11a-1, we also determined the effect of 
11a-1 on NIH 3T3 cell line which is non-tumorigenic and 
with significantly lower SHP2 expression in comparison 
to that in MeWo cell (Supplementary Figure S2A). As 
shown in Supplementary Figure S2B, the EC50 value 
of 11a-1 on NIH 3T3 cell viability (49.8 ± 5.2 μM) 
is more than 10 fold higher than that on MeWo cells, 
indicating that 11a-1 shows less toxicity to normal cells. 
To further consolidate the target engagement of SHP2, 
we evaluated two additional SHP2 inhibitors, one is a 
structurally-related active site-directed SHP2 inhibitor 
IIB08 (IC50 = 5.5 μM) [42], and the other is a structurally-
unrelated SHP2 inhibitor SHP099 (IC50 = 0.07 μM) with 
a different mode of action, namely allosteric inhibition, 
reported most recently by Novartis [43]. As shown in 
Supplementary Figure S2C and S2D, IIB08 and SHP099 
dose-dependently inhibit MeWo cell viability and SHP2 
mediated ERK1/2 activation. Collectively, these results 
indicate that 11a-1 inhibits MeWo cell viability through 
specifically inhibiting SHP2 mediated signaling pathways.
We further examined whether 11a-1 can neutralize 
SHP2’s positive effect on other cellular processes. MeWo 
cells treated with vehicle or 11a-1 were stained by Hoechst 
and anti-Ki67 antibody, visualized by an ArrayScan high-
content screening system and the Ki67-positive ratio was 
calculated to quantify cell proliferation. 11a-1 decreases 
the Ki67-positive ratio by 12% and 26% respectively 
at 10 and 20 μM, showing a dose-dependent inhibition 
on cell proliferation (Figure 4B). To assess the effect of 
SHP2 inhibition on cell motility, we treated MeWo cells 
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with vehicle or 11a-1, stained cell nucleus with Hoechst 
and monitored the mean moving distance of cells by an 
ArrayScan high-content screening system. As shown in 
Figure 4C, 11a-1 treatment dose-dependently shortens 
the mean moving distance of MeWo cells. The mean 
speed by the end of the experiments (6 hours duration) 
was calculated and normalized to vehicle treatment, and 
11a-1 was found to reduce the mean speed by 12% and 
23% respectively at 10 and 20 μM (Figure 4D). Similar 
inhibitory effects were also observed in B16F10 cells 
(Supplementary Figure S1B & S1C). We then proceeded 
to evaluate the effect of 11a-1 on cell migration by wound 
healing assay. As show in Figure 4E, 11a-1 slows down 
MeWo cell migration by ~25% and ~33% respectively at 
10 and 20 μM. Finally, we examined the effects of 11a-1 
on anchorage-independent growth of melanoma cells. As 
expected, 11a-1 effectively inhibits MeWo cell anchorage-
independent growth in a dose dependent manner, and 
almost completely blocks colony formation at 20 μM, 
while the negative control compound 10c barely shows 
any inhibition even at 20 μM (Figure 4F). This same 
inhibitory effect on anchorage-independent growth by 
11a-1 was also observed with the mouse melanoma cell 
B16F10 (Supplementary Figure S1D). Collectively, the 
results indicated that pharmacological inhibition of SHP2 
by 11a-1 can effectively inhibit melanoma cell viability, 
motility, and anchorage-independent growth, confirming 
the therapeutic potential of targeting SHP2 for melanoma 
treatment at cellular level.
11a-1 attenuates SHP2-mediated signaling 
pathways in melanoma cell
To delineate the molecular mechanisms underlying the 
mode of action of 11a-1 in melanoma cells, we performed 
Western blot analyses to evaluate its effects on SHP2 
relevant signaling pathways. The data shows that 11a-1 
decreases PCNA and increases cleaved PARP level 2 and 
5.5 fold after cells were treated with 10 and 20 M 11a-1 
for one day (Figure 5A), consistent with 11a-1’s ability to 
Figure 3: SHP2 positively regulate ERK1/2 and AKT signaling pathways. A. SHP2 overexpression promotes dephosphorylation 
of pPaxillin(Y118) and pSrc(Y527), as well as ERK1/2, AKT and S6K activation. Consistently, SHP2 knockdown attenuates 
dephosphorylation of pPaxillin(Y118) and pSrc(Y527), as well as ERK1/2, AKT and S6K activation under B. non-stimulation or C. HGF 
stimulation.
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suppress cell proliferation and induce apoptosis. Moreover, 
we also ascertained the effect of 11a-1 on SHP2-mediated 
ERK1/2 and PI3K/AKT pathway activation in MeWo cell. 
As shown in Figure 5B, 11a-1 dose-dependently augments 
the phosphorylation of Paxillin(Y118) and Src(Y527) 
and inhibits HGF-induced ERK1/2 activation. 11a-1 also 
inhibits AKT activation and consequently causes inhibition 
of downstream S6K activation. However, the inhibition 
of ERK1/2 and AKT activation were not observed after 
the negative control compound 10c treatment at 20 μM 
(Figure 5C), indicating target engagement of SHP2 in the 
signal transduction. Again, similar results were observed 
in B16F10 cells. 11a-1 inhibits HGF-induced ERK1/2 and 
AKT activation, but 10c shows no appreciable inhibition up 
to 20 μM (Supplementary Figure S3). Overall the data nicely 
showed that pharmacological inhibition of SHP2 by 11a-1 
phenocopied SHP2 knockdown.
11a-1 suppresses melanoma xenograft tumor 
growth
Given the observed promising activity of 11a-1 in 
blocking SHP2-mediated signaling in cell-based assays, 
we wanted to provide further proof-of-concept for 
targeting SHP2 for melanoma treatment. Pharmacokinetic 
(PK) analysis of plasma samples from a cohort of three 
mice collected at 1, 3, 6, 9, and 24 hr post-intraperitoneal 
(IP) injection of 11a-1 showed that 11a-1 displayed a very 
Figure 4: SHP2 inhibitor 11a-1 effectively inhibit mutiple processes in melanoma cell. 11a-1 dose-dependently inhibits 
MeWo cell A. viability B. proliferation C&D. motility E. migration and F. anchorage-independent growth.
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respectable PK profile with a maximum plasma compound 
exposure Cmax= 0.6 μM at 1 hr and a half-life t1/2=9.5 hr at 
a 10 mg/kg single dose (Supplementary Figure S4). Given 
the 11a-1’s excellent PK properties, we evaluated the 
efficacy of 11a-1 on melanoma tumor growth in vivo using 
a xenograft mouse model. MeWo cells were injected into 
one flank of each mouse, and the mice with grown tumors 
were randomly assigned to either a vehicle control group 
or an 11a-1 treatment group. Mice received IP injection of 
vehicle (DMSO) or 11a-1 (15 mg/kg) once daily, and the 
tumor growth was monitored for three weeks. As shown 
in Figure 6A, tumors in the vehicle-treated group progress 
steadily during the course of treatment, while tumor 
growth in 11a-1-treated group is significantly inhibited 
starting from the seventh day, and the average tumor 
volume is reduced 52% at day 21 compared to vehicle 
control. During the treatment period, the body weight of 
mice in both groups remained the same, indicating that 
11a-1 was well tolerated with no obvious toxicity (Figure 
6B). The mice were sacrificed after 21-day treatment, and 
the tumors were harvested and weighed. Tumors in the 
11a-1 treatment group are significantly smaller than those 
in vehicle control group (Figure 6C). Correspondingly, the 
tumor weight in 11a-1 group is also significantly reduced 
(Figure 6D). To study the effects of 11a-1 on SHP2-
mediated signaling pathways in vivo, tumor samples were 
lysed and analyzed by Western blot. Consistent with the 
observations in cultured MeWo cells, 11a-1 treatment leads 
to decreased pERK1/2 and pAKT level in xenograft tumor 
samples (Figure 6E). Moreover, the immunohistochemical 
analyses of tumor samples revealed that 11a-1 treatment 
reduced Ki67 level and elevated cleaved PARP level 
(Figure 6F), indicating that 11a-1 attenuated tumor cell 
proliferation and enhanced tumor cell apoptosis in vivo. 
We also evaluated the anti-melanoma effect of 11a-1 in 
syngeneic B16F10 melanoma xenograft mice, and found 
that 11a-1 significantly reduced melanoma xenograft 
tumor weight, as well as pERK1/2 and pAKT level in 
B16F10 melanoma xenograft tumor tissue (Supplementary 
Figure S5). Collectively, our results provide the first proof-
of-concept for the therapeutic potential of targeting SHP2 
for melanoma treatment.
DISCUSSION
During the past decade, great progress in targeted 
therapies and immunotherapies was made for melanoma 
treatment. However, the extension of life achieved by these 
agents is only several months due to the rapid occurrence 
of drug resistance [44]. Moreover, treatment for metastatic 
melanoma, which is linked with a poor patient prognosis, 
still remains limited. Melanoma progression involves 
a complex series of events, including malfunction of 
many signaling pathways and key oncogenic molecules. 
Elucidating the intricate mechanisms that initiate and drive 
melanoma and identification of new therapeutic targets 
Figure 5: 11a-1 inhibits SHP2-mediated signaling pathway. A. 11a-1 treatment leads to decreased proliferation marker PCNA and 
increased apoptosis marker cleaved PARP in MeWo cell. B. 11a-1 inhibits SHP2-mediated ERK1/2 and AKT signaling pathway in MeWo 
cell. C. Negative control 10c has no effect on ERK1/2 and AKT activation up to 20 μM.
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that might be crucial for clinical applications are likely to 
lead to more effective treatment strategies for melanoma.
SHP2 plays important roles in cell proliferation, 
migration, cell transformation, angiogenesis, and survival. 
SHP2 is a key signal-transducer acting downstream of most 
receptor tyrosine kinases including EGFR, FGFR, c-MET, 
Kit, PDGFR, and insulin receptor, and positively regulates 
Ras/ERK1/2, PI3K/AKT, JAK/STAT, JNK, FAK, NF-κB, 
and Wnt signaling pathways [12–15, 45]. Noticeably, 
some of the growth factor receptors and signaling 
pathways modulated by SHP2 are also implicated in 
melanoma pathogenesis, suggesting that SHP2 might play 
a role in melanoma onset or progression. To substantiate 
this speculation, we performed bioinformatics analyses 
and found that SHP2 mRNA level is elevated in melanoma 
compared to its precursor nevus. Moreover, high SHP2 
expression is significantly associated with more metastatic 
phenotype and poorer prognosis, and the survival time 
of patients with high SHP2 level is substantially shorter 
than those with low SHP2 level. The correlation between 
SHP2 expression and clinicopathological characteristics 
implicates a potential role of SHP2 in melanoma. In 
addition, given the obligatory requirement of SHP2 in 
receptor tyrosine kinase pathways, inhibition of SHP2 is 
expected to have therapeutic applications in a wide range 
of cancers including melanoma.
To disclose the role of SHP2 in melanoma 
pathogenesis and explore the potential of targeting SHP2 
for melanoma treatment, we first assessed the biological 
function of SHP2 in melanoma by overexpressing 
or knocking down SHP2 in MeWo cells. We found 
that SHP2 is a positive regulator of both ERK1/2 and 
AKT signaling, and promotes melanoma cell viability, 
anchorage-independent growth, and migration which 
are key characteristics in cancer cells progression and 
metastasis. These observations suggest that SHP2 acts 
as an oncogene involved in melanoma progression and 
metastasis, and support the notion that SHP2 may serve 
as a novel and promising target for melanoma treatment. 
Thereby, we proceeded to evaluate the effects of a small 
molecule SHP2 inhibitor 11a-1 on melanoma in cell 
culture and in vivo. Treatment of MeWo and B16F10 
metastatic melanoma cell lines with 11a-1 effectively 
blocks SHP2-mediated ERK1/2 and AKT activation and 
attenuates cell viability, anchorage-independent growth, 
and migration. Most importantly, 11a-1 significantly 
suppresses melanoma xenograft tumor growth, at least 
through reducing tumor cell proliferation and enhancing 
apoptosis. Our results validate SHP2 as a novel target 
for melanoma and suggest pharmacological inhibition of 
SHP2 could be highly effective therapeutic approach for 
melanoma treatment.
Finally, SHP2 plays important roles in several 
cellular processes, and there is a large body of literature 
implicating SHP2 as a bona fide oncoprotein. Moreover, 
since SHP2 is directly downstream of receptor tyrosine 
kinases, targeting the growth factor pathways at the 
level of SHP2 might offer unique advantages in receptor 
tyrosine kinase inhibitor resistance settings. This is of 
particular interest since several of the currently proposed 
drug resistance mechanisms against melanoma, through 
upregulation of C-Raf [46], B-Raf [47], hepatocyte growth 
Figure 6: 11a-1 suppresses MeWo melanoma cell xenograft tumor growth in vivo. A. 11a-1 significantly suppressed tumor 
growth since 7 days after treatment (n=9 for each group; *: p<0.05; **: p <0.01 B. 11a-1 treatment didn’t significantly change the body 
weight (n=9 for each group). C. 11a-1 treatment for 21 days significantly reduced tumor size. D. 11a-1 treatment for 21 days significantly 
reduced tumor weight (n=9 for each group; *: p<0.05). E. 11a-1 treatment led to decreased ERK1/2 and AKT activation in MeWo xenograft 
tumor samples. F. 11a-1 treatment inhibited cell proliferation and enhanced apoptosis in MeWo xenograft tumor samples.
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factor [48] or PDGFR [49], reactivate the signaling 
pathways which are mediated by SHP2. Indeed, a recent 
study indicates that SHP2 is a central node in intrinsic 
and acquired resistance to tyrosine kinase targeted cancer 
drugs [50]. However whether pharmacologic inhibition of 
SHP2 represents an effective approach for cancer therapy 
remains an outstanding question. Results from this study 
together with early reports [32, 51, 52] provide strong 
evidence that specific inhibitors of SHP2 can be effective 
anti-tumor agents. Future studies will investigate whether 
SHP2 inhibitors alone or in combination with kinase 
inhibitors can prevent or prolong the development of 
cancer drug resistance.
MATERIALS AND METHODS
Cells lines, antibodies and reagents
MeWo and B16F10 cell lines were purchased from 
the American Tissue Culture Collection. The following 
antibodies were from Cell Signaling Technology: phospho 
AKT (CAT. #: 4060), AKT (CAT. #: 2920), phospho 
ERK1/2 (CAT. #: 9101), ERK1/2 (CAT. #: 4696), phospho 
Paxillin (CAT. # 2541), phospho S6K (CAT. #: 9205), S6K 
(CAT. #: 9202), PCNA (CAT. #:2586), PARP (CAT. # 
9542), cleaved PARP (CAT. # 9541), phosphor Src (CAT. 
#: 2105), Src (CAT. #: 2108), horseradish peroxidase 
(HRP)-conjugated secondary antibodies (anti-mouse, 
CAT. #: 7076, anti-rabbit, CAT. #: 7074). The following 
antibodies were from Santa Cruz Biotechnology: GAPDH 
(CAT. #: sc-59541), SHP2 (CAT. #: sc-280), HA (CAT. 
#: sc-7392). Paxillin antibody (CAT. #: 610569) was 
from BD Transduction Laboratories. Ki67 antibody 
was from Thermo Fisher Scientific (CAT. # RM-
9106-S0). HGF, MTT (3-(4,5-Dimethylthiazol- 2-yl)-2,5-
diphenyltetrazolium bromide) were obtained from Sigma 
and prepared according to the manufacture’s instruction. 
Eagle’s Minimum Essential Medium (EMEM) and 
Dulbecco’s Modified Eagle’s Medium (DMEM) were 
from Corning, fetal bovine serum was from HyClone. 
SuperSignal West Dura Luminol/Enhancer solution 
was from Thermo Fisher Scientific. Lipofectamine® 
RNAiMAX and Lipofectamine® 2000 Transfection 
reagent was from Invitrogen Life Technologies.
Cell culture
MeWo cells were cultured at 37°C and 5% CO2 
in EMEM supplemented with 10% fetal bovine serum. 
B16F10 cells were cultured at 37°C and 5% CO2 in 
DMEM supplemented with 10% fetal bovine serum. 
To generate stably-transfected SHP2 cell lines, MeWo 
cells were transfected with pcDNA3.1-HA-SHP2 using 
Lipofectamine® 2000 transfection reagent according to 
manufacturer’s instruction, the transfected cells confer 
resistance to G418 thereby were selected in growth 
medium containing 1 mg/ml G418. Single-cell colonies 
were selected, expanded, and used in some experiments.
Immunoblot analysis
The cell lysates were resolved by SDS-PAGE and 
transferred onto nitrocellulose membranes. Membranes 
were blotted with various antibodies, and the blots were 
developed by the enhanced chemiluminescence technique 
using the SuperSignal West Pico Chemiluminescent 
substrate. Data shown in Figures is a representative result 
from one of multiple repeated experiments.
Cell viability assay
~4×103 cells were seeded in each well of 96-well 
plates. After treatment with different concentration of 11a-
1 for 2 days in 5% FBS containing medium, or incubation 
of overexpressed or knock down cells for 3 days in 10% 
FBS containing medium, cells were incubated with 50 
g/ml MTT for 3~4 hours. Then the culture medium was 
removed, DMSO was added to dissolve the formazan 
crystals. Wells containing only media were used for 
background correction. The optical density was measured 
spectrophotometrically at 540 nm.
Cell motility assay
~6×103cells /well were seeded in each well of a 96-
well plate. On the second day, 1μg/mL of Hoechst 33342 
(Thermo Scientific) was used to label the nuclei for 15min, 
and Thermo Scientific ArrayScan XTI Live High Content 
Platform was then used for live-cell tracking, image data 
were collected every 15 min and the motility of the cells 
was assessed over 4~6 h.
RNA interference studies
Small interfering RNA (siRNA) specific for 
SHP2 (5’- PCACGCAUGACGCCAUAUUCTT-3’) 
and scrambled SHP2 siRNA (5’- PGCACGACCGCC 
UUAUAACUTT-3’) were synthesized by Dharmacon 
Research. siRNAs were transfected into MeWo cells 
using Lipofectamine® RNAiMAX Reagent according to 
manufacturer’s instruction.
Immunofluorescence analysis
Cells were seeded in 96-well plates, fixed with 4% 
paraformaldehyde in phosphate-buffered saline (PBS) 
for 10 min at room temperature, permeabilized with 
0.1% Triton X-100 in PBS for 90 seconds, and blocked 
with 0.1% BSA in PBS for 1 hour. 0.1% BSA in PBS 
containing Ki67 antibody was applied overnight at 
4°C, followed by 1h incubation with anti-rabbit Alexa 
488 immunoglobulin G (Jackson ImmunoResearch 
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Laboratories). Then DNA staining with 5μg/mL Hoechst 
(Sigma) for another 15min was used for identification 
of cell nuclei. After washing with PBS, each well was 
filled with PBS. The fraction of Ki67 possitive cells 
were quantified by high content immunofluorescence 
microscope (Arrayscan™ XTI Infinity High Content 
Platform). In immunofluorescence analysis assessing the 
effect of 11a-1 on cell proliferation, cells were treated 
with 11a-1 or DMSO for 1 day before being fixed with 
4% paraformaldehyde contained PBS.
Wound healing assay
The uniform scratches were created using silicon 
culture inserts (Ibidi, Germany) with two individual 
wells for cell seeding according to the manufacturer’s 
instruction. After removing the inserts, cells were 
washed to remove the floating cells, and fresh medium 
containing 5% FBS was added. The photos were captured 
by EVOS FL cell imaging system (Life Technologies) at 
the indicated time points. The wound area was measured 
using MRI wound healing tool in Image J software, and 
the relative migration was calculated as described by Xia 
et al [53]: measure the initial wound area at 0 h as A0 
and the area at time point i as Ai, then the cell migration 
area at time point i is defined as Amigration(i) = Ai − A0, and 
the relative migration shown in Figures was calculated 
by normalizing the Amigration(i) for SHP2 versus vector 
overexpression cells (Figure 2F), or SHP2 siRNA versus 
scramble siRNA transfected cells (Figure 2G). In wound 
healing assay assessing the effect of 11a-1 on migration, 
11a-1 or DMSO were added to fresh medium containing 
5% FBS.
Soft agar colony formation assay
Cells were suspended in 0.3% agar containing 
medium and plated on a layer of 0.6% agar in medium 
in 12-well culture plates. After incubation for 4 weeks 
(Figure 2H) or 6 weeks (Figure 4F), colonies were 
stained with crystal violet and scanned with a scanner, the 
numbers of colonies and the percentage of colony-covered 
area were counted using Image J software.
Animal dosing and sample collection for 
pharmacokinetic studies
Three mice were administered a single IP dose of 
11a-1 at 10 mg/kg. At different time points (1 hour, 3 
hours, 6 hours, 9 hours and 24 hours), blood samples (50 
μl) from each mouse were collected and mixed with EDTA 
(50 mM, 50 μl). The samples were then mixed with 200 
μl acetonitrile and centrifuged at 21,100 g for 5 minutes. 
The supernatants were collected and subjected to liquid 
chromatography/mass spectrometry analysis.
Liquid chromatography/mass spectrometry 
analysis
The Liquid Chromatography/Mass Spectrometry 
(LC/MS) analysis was carried out on a Agilent 1200 
analytic HPLC system and an Agilent 6130 Quadrupole 
MS detector, equipped with a Phenomenex Kinetex 2.6u 
XB-C18 column (2.5 μm, 4.6 mm X 50 mm), eluted 
with 0-100% MeOH-H2O with 0.1% (w/v) ammonium 
bicarbonate at 0.8 mL/min flow-rate (gradient method: 
9.0 min 0-90% MeOH linear gradient, followed by 3 min 
90-100% MeOH, followed by 3 min 100% MeOH), MS 
detector were set at single ion mode (SIM), monitoring the 
negative charge 636 (M-1). The detection limit for 11a-1 is 
50 nM at 2 μl sample injection.
Tumor xenograft experiments
NSG (NOD/scid/IL2Rgnull) mice were purchased 
from In Vivo Therapeutics Core of the Indiana University 
Simon Cancer Center. Xenograft experiments were 
performed in compliance with the relevant laws and 
guidelines set forth by the Institutional Laboratory 
Animal Care and Use Committee of Indiana University. 
All mice were housed under pathogen-free conditions 
in the animal facility and received autoclaved water and 
food. 10-12 weeks old NSG mice were used in the study. 
MeWo cells were suspended in phosphate-buffered saline 
(PBS) at 8×107 cells/ml. A total of 8×106 cells (100 μl) 
were subcutaneously implanted into both left and right 
flank using a 27-gauge needle. Tumor size was measured 
with calipers. Tumor volume (V) was determined by the 
equation V = (L × W2) × 0.5, in which L is the length 
and W is the width of the tumor. When tumors reached 
volumes of ~200 mm3, the mice showing tumors were 
randomly assigned to a control group and an 11a-1 group, 
and daily intraperitoneal injection of either vehicle or 15 
mg/kg 11a-1 was performed, and the tumor growth was 
monitored for 3 weeks. Mice were sacrificed after injection 
for 21 days, and tumors were removed, weighted, as well 
as subjected to immunohistological and biochemical 
analysis.
Immunohistochemistry analysis
Harvested tissues were fixed in 4% paraformaldehyde 
overnight at 4°C, embedded in paraffin, serially sectioned 
(7 μm), de-paraffined sections were incubated with 
diluted antibodies at 4°C overnight. Signals were detected 
by VECTASTAIN Elite ABC kit and developed using 
DAB substrate from Vector laboratory (Burlingame, 
CA). All the antibodies used were from Cell Signaling 
Technology. Images were captured on a Leica DM2500 
stereomicroscope.
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Statistical analysis
In clinical relevance study of SHP2 in melanoma, the 
data was downloaded from Oncomine or TCGA database. 
The Student’s t-test was used to assess the significance 
of differences between groups. Survival analysis was 
performed according to the Kaplan-Meier method and the 
log-rank test was used to assess the significance. For all 
cell-based assays, each experiment was repeated for 2~3 
times, the representative result was shown in figures, the 
bar chart represented mean value ± standard deviation, and 
the Student’s t-test was used to measure the significance. 
In xenograft tumors experiments, tumor volumes at 
different time point, as well as final tumor weights were 
compared between 11a-1 and vehicle treated group, the 
statistical significance was evaluated using the Student’s 
t-test. In all statistical analysis, p-value less than 0.05 
was considered statistically significant, and the statistical 
significance were represented in figures as * (p < 0.05), ** 
(p < 0.01) or *** (p < 0.005).
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